Skip to main navigation

Skip to main content

Home

Home

About

About Liquidia

Products and Pipeline

Pipeline and Products

IR Nav

Investors

Careers

Careers
- Overview
- Jobs
- Benefits
- Principles

Contact Us

Contact Us
- Overview
- Map/Directions

Event

IR Nav

Investors

Overview
Press Releases
Events & Presentations
Stock Information
Analyst Coverage Stock Quote & Chart Historical Price Lookup Investment Calculator
Corporate Governance
Documents & Charters Leadership Board of Directors Committee Composition
SEC Filings
IR Resources
Investor FAQs IR Contact Email Alerts

Liquidia Second Quarter 2019 Financial Results and Corporate Update Call

Aug 8, 2019 at 8:00 AM EDT

Click here for webcast

IR Tools

Print Page
Share
RSS

Request Email Alerts

PO Box 110085, Research Triangle Park, NC 27709
Tel +1 919-328-4400
Fax +1 919-328-4402

Socials

© 2021 Liquidia, Inc. All Rights Reserved.

Liquidia is a biopharmaceutical company focused on the development and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary arterial hypertension (PAH). Our pipeline is focused on the development of two product candidates using our PRINT^® Technology platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain.

Our subsidiary, Liquidia PAH (formerly RareGen), generates revenue pursuant to a promotional agreement between RareGen and Sandoz, sharing profit derived from the sale of the first-to-file fully substitutable generic treprostinil injection, or Treprostinil Injection, in the United States.

Legal Nav

Legal
Privacy
Cookies
Social Media

Facebook
Twitter
LinkedIn